Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Neoplasms 1Mesothelioma, Malignant 1Hemangioma, Capillary 1Cerebral Hemorrhage 1Brain Neoplasms 1Arteriovenous Malformations 1

Interventions

Pemetrexed 4Cisplatin 4pembrolizumab 3Nivolumab 3Interleukin-2 3Carboplatin 3atezolizumab 2aldesleukin 2Pharmaceutical Preparations 2Ipilimumab 2olaparib 1lenvatinib 1fludarabine 1enzalutamide 1Thoracoscopy 1Thoracic Surgery, Video-Assisted 1Surgery, Computer-Assisted 1Proton Therapy 1Platinum 1Paclitaxel 1Injections 1Influenza Vaccines 1Indocyanine Green 1In Situ Hybridization, Fluorescence 1Cyclophosphamide 1Combined Modality Therapy 1Cerebral Decortication 1Brentuximab Vedotin 1Blood Component Removal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Mesothelioma, Malignant × Surgery, Computer-Assisted × Clear all
NCT03760575 2025-12-04

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Abramson Cancer Center at Penn Medicine

Phase 1 Recruiting
20 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡